This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Indications

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The principal use is in renal failure; priority indicators include:

  • transfusion dependency
  • angina - heart failure aggravated by anaemia
  • haemoglobin concentrations less than 8
  • livelihood threatened by anaemia
  • prevention of sensitisation to transplantation antigens

Other uses include:

  • patients anaemic due to malignant disease - improves anaemia, but quality of life probably not increased
    • there are concerns about using erythopoietin in patients with cancer:
      • study evidence revealed that erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of venous thromboembolism (VTE) and mortality (1)

  • rheumatoid arthritis:
    • corrects anaemia
    • results in clinical improvement

  • Jehovah's witnesses:
    • useful following major surgery

  • haematologic disorders:
    • safe and effective in lymphoproliferative disorders
    • less good in haematopoietic disorders
    • iron deficiency is an important cause of failure to respond

Reference:

 


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page